Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EFTR

eFFECTOR Therapeutics Inc

May 10 • 04:00PM ET

2.03

Dollar change -0.11
Percentage change -5.14	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.12	Insider Own	12.67%	Shs Outstand	4.70M	Perf Week	-7.73%
Market Cap	9.54M	Forward P/E	-	EPS next Y	-2.25	Insider Trans	-50.57%	Shs Float	4.11M	Perf Month	-9.17%
Income	-34.63M	PEG	-	EPS next Q	-1.74	Inst Own	7.63%	Short Float	3.12%	Perf Quarter	-81.03%
Sales	0.00M	P/S	-	EPS this Y	65.64%	Inst Trans	-60.62%	Short Ratio	0.33	Perf Half Y	-86.65%
Book/sh	0.21	P/B	9.58	EPS next Y	60.00%	ROA	-141.18%	Short Interest	0.13M	Perf Year	-84.16%
Cash/sh	5.40	P/C	0.38	EPS next 5Y	-	ROE	-946.56%	52W Range	1.60 - 37.00	Perf YTD	-82.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.64%	ROI	-3442.35%	52W High	-94.51%	Beta	0.93
Dividend TTM	-	Quick Ratio	1.03	Sales past 5Y	-40.00%	Gross Margin	84.00%	52W Low	26.87%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	1.03	EPS Y/Y TTM	57.66%	Oper. Margin	0.00%	RSI (14)	31.46	Volatility	8.09% 9.92%
Employees	14	Debt/Eq	23.07	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	65.67
Option/Short	No / Yes	LT Debt/Eq	0.22	EPS Q/Q	-807.89%	Payout	-	Rel Volume	0.22	Prev Close	2.14
Sales Surprise	-	EPS Surprise	0.23%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	391.01K	Price	2.03
SMA20	1.70%	SMA50	-73.42%	SMA200	-83.45%	Trades		Volume	85,112	Change	-5.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-22	Downgrade	Stifel	Buy → Hold	$20 → $6.20
Nov-09-21	Upgrade	Stifel	Hold → Buy	$20
Oct-12-21	Initiated	Credit Suisse	Outperform	$20
Oct-04-21	Initiated	Mizuho	Buy	$20
Sep-21-21	Initiated	JMP Securities	Mkt Outperform	$33
Sep-20-21	Initiated	Stifel	Hold	$20
Sep-13-21	Initiated	Cantor Fitzgerald	Overweight	$50

May-09-24 10:56PM	EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
04:01PM	eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-09-24 08:00AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conference (GlobeNewswire) +8.45%
Apr-05-24 12:58PM	eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails (Zacks) -15.20%
Apr-04-24 08:30AM	eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer (GlobeNewswire) -82.03%
09:53PM	Loading…
Mar-25-24 09:53PM	EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.60%
04:01PM	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-05-24 08:30AM	eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-24 09:55AM	Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect? (Zacks)
Jan-29-24 04:05PM	eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +10.90%
Jan-25-24 08:00AM	eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -8.74%
Jan-09-24 08:05AM	eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 (GlobeNewswire) -19.87%
08:00AM	eFFECTOR Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Dec-08-23 08:15AM	eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients (GlobeNewswire) -9.02%
Nov-28-23 08:00AM	eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer (GlobeNewswire)
08:00AM	Loading…
Nov-15-23 08:00AM	eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting (GlobeNewswire)
Nov-13-23 04:14PM	eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.42%
Nov-06-23 08:00AM	eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference (GlobeNewswire) +5.44%
Oct-24-23 08:00AM	eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia (GlobeNewswire)
Sep-11-23 08:00AM	eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors (GlobeNewswire)
Aug-30-23 08:00AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-23 06:05AM	eFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022) (Simply Wall St.)
Aug-08-23 04:01PM	eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-08-23 04:01PM	eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings (GlobeNewswire)
Jun-07-23 08:00AM	eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -7.19%
May-31-23 05:43PM	eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +12.97%
May-26-23 09:00AM	eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +24.76%
May-25-23 04:50PM	eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting (GlobeNewswire) -23.83%
May-09-23 04:01PM	eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 08:00AM	eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire) +10.34%
04:01PM	Loading…
Apr-26-23 04:01PM	eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting (GlobeNewswire) -8.78%
Apr-11-23 08:00AM	eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer (GlobeNewswire) +7.28%
Mar-28-23 08:30AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-08-23 04:01PM	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.15%
Feb-21-23 08:30AM	eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID (GlobeNewswire) -18.09%
Jan-30-23 08:00AM	eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference (GlobeNewswire)
Jan-05-23 04:01PM	eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update (GlobeNewswire) -17.67%
Nov-07-22 04:00PM	eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.53%
Oct-31-22 02:05PM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-26-22 08:00AM	eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 (GlobeNewswire)
Sep-26-22 08:00AM	eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer (GlobeNewswire)
Sep-21-22 09:00AM	eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference (GlobeNewswire)
Sep-14-22 08:00AM	eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 (GlobeNewswire)
Sep-06-22 08:30AM	eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 04:01PM	eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -27.35%
Aug-08-22 05:30AM	eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer (GlobeNewswire) +9.30%
Jun-07-22 08:00AM	eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire) -6.47%
Jun-05-22 05:00PM	eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity (GlobeNewswire)
May-26-22 05:15PM	eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting (GlobeNewswire)
May-10-22 04:02PM	eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 06:45AM	How Much Of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Do Institutions Own? (Simply Wall St.)
May-02-22 04:04PM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -11.11%
Apr-04-22 08:30AM	eFFECTOR Therapeutics Announces Transition in Clinical Leadership (GlobeNewswire)
Mar-16-22 04:01PM	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-16-22 08:30AM	eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors (GlobeNewswire)
Feb-15-22 06:53PM	2 Strong Buy Stocks That Could Be Bought Out, According to Credit Suisse (TipRanks)
Feb-09-22 04:00PM	eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference (GlobeNewswire)
Jan-24-22 04:00PM	eFFECTOR Therapeutics Provides Pipeline and Business Updates (GlobeNewswire) -6.07%
Nov-24-21 08:00AM	eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology (GlobeNewswire)
Nov-22-21 08:00AM	eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-08-21 07:00AM	eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +6.21%
Nov-04-21 09:08AM	Do Institutions Own eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Shares? (Simply Wall St.)
Nov-01-21 04:05PM	eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors (GlobeNewswire)
Oct-26-21 08:00AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-07-21 04:30PM	Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-30-21 04:32PM	Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-16-21 08:00AM	eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference (GlobeNewswire) +5.84%

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Nov 27 '23	Sale	0.61	609,163	369,457	1,821,415	Nov 29 05:07 PM
WORLAND STEPHEN T	Chief Executive Officer	Aug 11 '23	Option Exercise	0.52	33,799	17,575	261,225	Aug 14 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EFTR

eFFECTOR Therapeutics Inc

Upgrade your FINVIZ experience